Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00176774 · ClinicalTrials.gov registry record · Phase 2
Irinotecan, 5-Fluorouracil, and Leucovorin in Colorectal Carcinoma
A Phase 2 study, sponsored by University of Michigan Rogel Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
NCT00176774 is a Phase 2 study that has completed, run by University of Michigan Rogel Cancer Center. The registered enrollment target is 24 participants.
The verdict
NCT00176774, a Phase 2 study, has completed, sponsored by University of Michigan Rogel Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
Study Summary
This study will examine an investigational (experimental) agent Tetrathiomolybdate (TM) combined with the chemotherapy drugs Irinotecan, 5-Fluorouracil (5-FU) and Leucovorin (LV). This study will evaluate the safety and tolerability of the combination of these drugs when they are used in the treatment of metastatic colorectal cancer. This is a pilot clinical trial which will be studying the reactions of the patient's body and tumor to the experimental treatment described above. The purpose of this study is to find out what kind of side effects this experimental treatment causes and see how often these side effects occur.
Interventions
- DRUG Leucovorin
- DRUG Irinotecan
- DRUG 5-Fluorouracil
- DRUG Tetrathiomolybdate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2001-02 |
| Est. Completion | 2004-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00176774
The ClinicalTrials.gov registry entry for NCT00176774 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Michigan Rogel Cancer Center, which has 292 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Leucovorin is the first listed.
NCT00176774 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00176774 about?
NCT00176774 is a clinical study titled "Irinotecan, 5-Fluorouracil, and Leucovorin in Colorectal Carcinoma". This study will examine an investigational (experimental) agent Tetrathiomolybdate (TM) combined with the chemotherapy drugs Irinotecan, 5-Fluorouracil (5-FU) and Leucovorin (LV). This study will evaluate the safety and tolerability of the combination of these drugs when they are used in the treatme...
What is the current status of trial NCT00176774?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2001-02. Estimated completion is 2004-04.
What interventions are being tested in trial NCT00176774?
The interventions under investigation include: Leucovorin (DRUG), Irinotecan (DRUG), 5-Fluorouracil (DRUG), Tetrathiomolybdate (DRUG).
Who is sponsoring clinical trial NCT00176774?
This trial is sponsored by University of Michigan Rogel Cancer Center, which has 292 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.